Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Age ≥ 18 years and ≤ 65 years

• Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)

• Any stage of disease (nodal or extra-nodal), with or without B symptoms

• Scheduled to receive standard systemic treatment (R-CHOP)

• ECOG performance status 0-2

• Baseline normal:

• Complete blood count (CBC)

• Hepatitis viral markers

• Liver and renal function tests

• Urine analysis

• Echocardiogram

• Additional investigations to exclude current infection if clinically indicated

Locations
Other Locations
Egypt
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University
RECRUITING
Cairo
Contact Information
Primary
Alaa M Elsayed, MSc
alaa.abdou@med.asu.edu.eg
+201112490913
Time Frame
Start Date: 2025-05-05
Estimated Completion Date: 2026-08
Participants
Target number of participants: 40
Treatments
Patients with DLBCL Treated with R-CHOP (Observational Group)
Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who are receiving R-CHOP chemotherapy as part of standard clinical care. This observational study aims to evaluate the predictive value of baseline inflammatory markers (CRP, albumin, CAR, and mGPS) on treatment response and toxicity. No study-specific interventions are administered.
Related Therapeutic Areas
Non-Hodgkin Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsors
Leads: Ain Shams University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients

realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients

Enrollment Status: Recruiting
Publish Date: December 10, 2024
Intervention Type: Drug

A Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Enrollment Status: Recruiting
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 3

Characterization and Clinical Impact of the Gut Microbiota in Diffuse Large B-cell Lymphoma Patients

Characterization and Clinical Impact of the Gut Microbiota in Diffuse Large B-cell Lymphoma Patients

Enrollment Status: Recruiting
Publish Date: August 09, 2024
Intervention Type: Diagnostic test
View All